Leerink Partnrs Has Pessimistic Outlook of ELAN Q1 Earnings

Elanco Animal Health Incorporated (NYSE:ELAN) – Research analysts at Leerink Partnrs cut their Q1 2025 earnings estimates for Elanco Animal Health in a research report issued to clients and investors on Tuesday, February 25th. Leerink Partnrs analyst D. Clark now anticipates that the company will post earnings of $0.29 per share for the quarter, down from their prior estimate of $0.32. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health’s Q2 2025 earnings at $0.26 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.13 EPS, FY2025 earnings at $0.80 EPS, FY2027 earnings at $1.16 EPS and FY2028 earnings at $1.37 EPS.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.08 EPS.

ELAN has been the subject of a number of other research reports. UBS Group decreased their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday. Morgan Stanley decreased their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research note on Wednesday. Leerink Partners started coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price target for the company. Barclays decreased their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday. Finally, Stifel Nicolaus decreased their price target on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $15.83.

Elanco Animal Health Trading Down 1.8 %

Shares of ELAN stock opened at $10.93 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The stock has a market capitalization of $5.40 billion, a P/E ratio of 27.31, a price-to-earnings-growth ratio of 2.50 and a beta of 1.42. The company has a 50 day moving average price of $11.72 and a 200 day moving average price of $13.05. Elanco Animal Health has a fifty-two week low of $10.20 and a fifty-two week high of $18.80.

Institutional Trading of Elanco Animal Health

Several institutional investors have recently modified their holdings of ELAN. FMR LLC lifted its position in shares of Elanco Animal Health by 1,153.6% during the 4th quarter. FMR LLC now owns 40,232,327 shares of the company’s stock worth $487,213,000 after buying an additional 37,022,891 shares during the last quarter. JPMorgan Chase & Co. raised its position in Elanco Animal Health by 76.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company’s stock valued at $147,747,000 after purchasing an additional 4,361,799 shares during the last quarter. Norges Bank purchased a new stake in Elanco Animal Health in the 4th quarter valued at $47,424,000. Brandes Investment Partners LP raised its position in Elanco Animal Health by 66.9% in the 4th quarter. Brandes Investment Partners LP now owns 5,731,180 shares of the company’s stock valued at $69,405,000 after purchasing an additional 2,296,691 shares during the last quarter. Finally, Freestone Grove Partners LP purchased a new stake in Elanco Animal Health in the 4th quarter valued at $20,396,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.